A new trade deal between the U.S. and Mexico, in which the patent protection of biologic medicines is set for 10 years could have implications for Canada’s drug expenditure, and is a point of contention for Canada’s trade negotiators.
Canada currently has a patent protection period of 8 years for biologic drugs, so any increase would significantly affect its drug expenditure.
The PMPRB annual sales report for 2017, released last week, highlights the recent growth of biologic medicines in Canada, from 16% of total patented medicines costs in 2008 to 42% in 2017. In addition, 7 of the top 10 medicines that contributed to growth in patented medicines sales from 2016 to 2017 were biologics.
The full PMPRB report can be read here.